Evidence map›Paper›PMID 40148300›Full record

ReviewCurrent drug safety2026

Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report.

Myriam Ayari, Maha Mtir, Ikram Mami, Lamia Rais, Sarah Ben Azouz, Hedi Douggui, Taieb Jomni

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Current drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Myriam AyariDepartment of Gastroenterology, Internal Security Forces Hospital La Marsa, Tunis, Tunisia.ORCID 0000-0001-7361-8248
Maha MtirDepartment of Gastroenterology, Internal Security Forces Hospital La Marsa, Tunis, Tunisia.
Ikram MamiDepartment of Nephrology, La Rabta Hospital, Tunis, Tunisia.
Lamia RaisDepartment of Nephrology, La Rabta Hospital, Tunis, Tunisia.
Sarah Ben AzouzDepartment of Gastroenterology, Internal Security Forces Hospital La Marsa, Tunis, Tunisia.
Hedi DougguiDepartment of Gastroenterology, Internal Security Forces Hospital La Marsa, Tunis, Tunisia.
Taieb JomniDepartment of Gastroenterology, Internal Security Forces Hospital La Marsa, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with inflammatory disease treated with biological agents are at an increased risk of developing various adverse effects. However, little is known about the risk of nephrotoxicity, such as induced tubulointerstitial nephritis and immune-mediated inflammatory diseases involving the interstitium and renal tubule. CASE PRESENTATION: We herein describe a case of biopsy-proven tubulointerstitial nephritis, induced by PR3-ANCA-associated vasculitis following adalimumab therapy in a patient with Crohn's disease and ankylosing spondylitis. We review the current evidence on adalimumabinduced nephrotoxicity and the potential underlying mechanisms.

conclusionMonitoring of renal function is strongly recommended in all patients treated with adalimumab. Early diagnosis of drug-induced tubulointerstitial nephritis due to vasculitis and immediate withdrawal of the offending drug are key to renal recovery and prevention from irreversible serious organ damage.

Indexed as

AdalimumabAnti-Inflammatory AgentsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNephritis, InterstitialCrohn DiseaseHumansMaleSpondylitis, AnkylosingAdalimumabAnti-Inflammatory AgentsAdalimumabadverse drug reactionANCA-associated vasculitisankylosing spondylitisbiological therapyCrohn diseasetubulointerstitial nephritis

Identifiers

PMID40148300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.